Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 63 clinical trials
featured
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)

A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)

  • 106 views
  • 08 Nov, 2020
  • 1 location
featured
A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative

  • 90 views
  • 25 Mar, 2021
  • 1 location
featured
Ulcerative Colitis

Ulcerative Colitis

  • 28 views
  • 08 Nov, 2020
  • 1 location
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional

tumor necrosis factor
immunosuppressive agents
mycophenolate
monoclonal antibodies
tacrolimus
  • 111 views
  • 02 Aug, 2021
  • 33 locations
UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis

Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis. However, in a portion of cases

tumor necrosis factor
adalimumab
phototherapy
tumor necrosis factor alpha
  • 1 views
  • 07 Nov, 2020
  • 1 location
Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis

with adalimumab 40 mg s.c. eow compared to infliximab 3 mg/kg i.v. every 6 weeks.

adalimumab
infliximab
  • 35 views
  • 07 Nov, 2020
  • 5 locations
Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis

, reversible and competitive inhibitor of Janus kinases (Jaki). This treatment is efficient in a number of therapeutic scenarios in RA and showed a clinical superiority over adalimumab in one RCT (RA-BEAM

tumor necrosis factor
tumour necrosis
DMARD
remission
anakinra
  • 0 views
  • 21 Jul, 2021
  • 20 locations
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

rheumatoid arthritis. Etanercept is a fusion protein with TNF receptor type II p75 and IgG1 Fc fragment, whereas adalimumab, infliximab, and golimumab are monoclonal antibodies. Certolizumab is a fusion

DMARD
rheumatoid arthritis
biological therapy
tnf blocker
NSAID
  • 17 views
  • 04 Aug, 2021
  • 35 locations
Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis

This study conducted a systematic clinical observation of the clinical efficacy of UCB-MNCs in the treatment of hormone-resistant or hormone-dependent ulcerative colitis, in order to observe its clinical safety and efficacy.

adalimumab
azathioprine
prednisone
  • 0 views
  • 22 May, 2021
  • 1 location
Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade

The SPARTACUS study will explore the therapeutic efficacy of 2 different treatment strategies for patients suffering from peripheral Spondyloarthritis (pSpA), classified according to the "Assessment in SpondyloArthritis international Society" (ASAS) classification criteria; it will be set up as a 48-week, prospective, randomized, active-comparator controlled, double-blind, double-dummy, clinical trial with a …

  • 0 views
  • 24 Feb, 2021
  • 6 locations